Ellie Baker

AI
Medical imaging AI market expected to exceed $1.7B by 2027
The medical imaging AI market is projected to produce a 25% growth rate and exceed $1.73 billion by 2027, according to a new article by Ellie Baker, a market analyst at Signify Research.
July 18, 2023
2023 07 18 21 47 9959 2023 07 18 Baker Ellie 400 20230718214630
Page 1 of 1
Top Stories
Voxel-based morphometry (VBM) group comparison of grey matter brain volumes. TFCE-corrected significance map shown (one-tailed t-test; higher significance indicated by light blue color). (a) Comparison between ex-soccer players (n = 124) and controls (n = 40). (b) Comparison between ex-rugby players (n = 200) and controls (n = 33) from Graham & Zimmerman et al. (2025), reproduced with permission under Creative Commons license.
MRI
MRI shows higher neuro symptom burden for former soccer players
Former elite soccer players have lower white matter volume and report higher levels of depression and anxiety.
Pe
CT
Clinical tool can reduce the use of CPTA in cancer patients
County-level net change in radiation oncology practice sites from first appearance through 2025.
Radiation Oncology/Therapy
ASTRO highlights study on disappearing radiation oncology centers
Ctca
CT
CCTA finds coronary disease in men with erectile dysfunction
Marijuana
CT
Marijuana use linked to greater coronary plaque burden
More in Home
MRI shows higher neuro symptom burden for former soccer players
By Amerigo Allegretto
Former elite soccer players have lower white matter volume and report higher levels of depression and anxiety.
July 13, 2026
Voxel-based morphometry (VBM) group comparison of grey matter brain volumes. TFCE-corrected significance map shown (one-tailed t-test; higher significance indicated by light blue color). (a) Comparison between ex-soccer players (n = 124) and controls (n = 40). (b) Comparison between ex-rugby players (n = 200) and controls (n = 33) from Graham & Zimmerman et al. (2025), reproduced with permission under Creative Commons license.
Clinical tool can reduce the use of CPTA in cancer patients
By Will Morton
The YEARS algorithm obviated the need to perform CTPAs in 22% of patients without increasing the risk of a missed blood clot.
July 13, 2026
Pe
ASTRO highlights study on disappearing radiation oncology centers
By Amerigo Allegretto
Over two-thirds of all U.S. counties reported lacking a radiation oncology practice site in 2025.
July 10, 2026
County-level net change in radiation oncology practice sites from first appearance through 2025.
CCTA finds coronary disease in men with erectile dysfunction
By Will Morton
Erectile dysfunction caused by vascular problems is associated with a higher risk of coronary artery disease.
July 10, 2026
Ctca
Marijuana use linked to greater coronary plaque burden
By Will Morton
Marijuana users demonstrated more than double coronary artery calcium scores than nonusers.
July 10, 2026
Marijuana
CEM on par with MRI for breast cancer diagnosis, local staging
By Amerigo Allegretto
CEM alone in a prospective study achieved perfect sensitivity and negative predictive value in diagnosing breast cancer.
July 10, 2026
MRI false positive for additional disease, (top to bottom): A. Index lesion—grade 2 invasive ductal carcinoma; B. MRI lesion two, upper inner quadrant: Stromal sclerosis and columnar cell change; C. MRI lesion three, upper outer quadrant: No ultrasound correlate, no malignancy on follow-up; D. CEM marked background parenchymal enhancement with a unifocal retroareolar lesion demonstrating wash-out on delayed MLO. Images are republished under a Creative Commons license (CC BY 4.0).
Ultrasound MinnieCast, Episode 12: AI adds to ultrasound in global maternity care
By Amerigo Allegretto
Researchers from Google Research share results of a study on an AI ultrasound model estimating gestational age in pregnant women.
July 10, 2026
Minnie Cast Thumbnail (14)
New PET tracer show promise in neuroblastoma
By Will Morton
F-18 mFBG achieved a pooled sensitivity of 97%, compared with 82% for I-123 MIBG.
July 9, 2026
Cancer Target
AI ultrasound model accurately estimates gestational age
By Amerigo Allegretto
The model achieved noninferiority compared to standard clinical assessments in healthcare settings based in the U.S. and Africa.
July 9, 2026
Ultrasound In Africa 400
AR-guided localization may sub for CT for early-stage lung cancer
By Amerigo Allegretto
AR-guided localization was noninferior to conventional CT guidance and led to better patient experiences.
July 8, 2026
Lungs 3 D Research 400
Study backs LDCT lung cancer screening in Singapore
By Will Morton
Lung cancer is the leading cause of cancer death in Singapore, with approximately 48% of cases occurring in individuals who have never smoked.
July 8, 2026
Lungs
New criteria evaluates treatment response in bone metastases
By Will Morton
RECIBM-defined response classifications showed high agreement with established criteria and reclassified 19% of patients.
July 7, 2026
Response Evaluation Criteria in Bone Metastases (RECIBM) and metabolic criteria were used to detect a complete response missed at anatomic assessment. A 76-year-old male patient presented with 1 month of hemoptysis and was diagnosed with small cell lung cancer and bone metastases. Baseline (July 2022) F-18 FDG-PET/CT images (A, maximum intensity projection image; B–E, axial images) demonstrate FDG-avid lesions in the left lamina of the first lumbar vertebra (L1) (straight yellow arrows; maximum standardized uptake value, 2.74; peak standardized uptake value normalized to lean body mass, 1.59) and left ilium (curved yellow arrows; maximum standardized uptake value, 3.68; peak standardized uptake value normalized to lean body mass, 2.28). After seven chemotherapy cycles (December 2022), follow-up PET/CT images (F, maximum intensity projection image; G–J, axial images) show complete metabolic resolution of bony lesions (L1: maximum standardized uptake value, 1.32, and peak standardized uptake value normalized to lean body mass, 0.85; left ilium: maximum standardized uptake value, 1.48, and peak standardized uptake value normalized to lean body mass, 0.82), without apparent osteolytic or osteoblastic changes at CT. Assessment was stable disease (SD) according to the University of Texas MD Anderson Cancer Center (MDA) criteria but complete response (CR) or complete metabolic response (CMR) according to RECIBM, PET Response Criteria in Solid Tumors (PERCIST), and European Organization for Research and Treatment of Cancer (EORTC) criteria. The patient was alive as of September 30, 2025.
Page 1 of 238
Next Page